MEDICAL CHANNEL ASIA

PUBLIC PORTAL

PUBLIC PORTAL

MEDICALLY REVIEWED

Esketamine (Spravato) for Treatment Resistant Depression

esketamine (spravato) treatment resistant depression

The Disease Burden
Esketamine (Spravato) by Johnson and Johnson, received local market authorization in October 2021 for use ‘with an oral antidepressant (SSRI or SNRI) in treatment-resistant depression (TRD)’, which is defined as major depressive disorder (MDD) in adults who have not responded adequately to at least . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: